Short Communication

AGE Metabolites: A Biomarker Linked to Cancer Disparity?

Dion Foster1, Laura Spruill1, Katherine R. Walter1, Lourdes M. Nogueira1, Hleb Fedarovich1, Ryan Y. Turner1, Mahtabuddin Ahmed2, Judith D. Salley2, Marvella E. Ford3, Victoria J. Findlay1,3, and David P. Turner1,3

Abstract

Socioeconomic and environmental influences are established factors promoting cancer disparity, but the contribution of biologic factors is not clear. We report a mechanistic link between carbohydrate-derived metabolites and cancer that may provide a biologic consequence of established factors of cancer disparity. Glycation is the nonenzymatic glycosylation of carbohydrates to macromolecules, which produces reactive metabolites called advanced glycation end products (AGE). A sedentary lifestyle and poor diet all promote disease and the AGE accumulation pool in our bodies and also increase cancer risk. We examined AGE metabolites in clinical specimens of African American and European American patients with prostate cancer and found a higher AGE concentration in these specimens among African American patients when compared with European American patients. Elevated AGE levels corresponded with expression of the receptor for AGE (RAGE or AGER). We show that AGE-mediated increases in cancer-associated processes are dependent upon RAGE. Aberrant AGE accumulation may represent a metabolic susceptibility difference that contributes to cancer disparity. Cancer Epidemiol Biomarkers Prev; 23(10); 2186–91. ©2014 AACR.

Introduction

African American patients with prostate cancer are more likely to develop aggressive prostate cancer and die of their disease than their European American counterparts (1–4). Poor diet and a lack of physical activity are potential risk factors for prostate cancer. Men who eat higher quantities of red meat and dairy products rather than fresh fruits and vegetables may have a higher chance of developing prostate cancer (5, 6). A healthy diet may also associate with improved clinical outcome and increased quality of life (6). Although no association between physical activity and prostate cancer risk has yet been identified, research suggests that it may be associated with reduced risk of aggressive disease (7). Increased physical activity is also associated with increased survival in patients with prostate cancer after diagnosis (8).

It is becoming increasingly apparent that molecular differences in tumor biology play a significant role in cancer disparity. In particular, established factors such as low income, poor diet, and a sedentary lifestyle may confer molecular effects that alter cell signaling and gene expression patterns, including expression of noncoding RNAs, and affect chromosomal stability and therefore accelerate tumor development and progression (1–4). In other words, our lifestyle choices may have profound effects on tumor development and progression, which may contribute to health disparity outcomes such as the earlier development of cancer or the progression to more aggressive disease. Combined approaches to define the molecular consequences of the socioeconomic and environmental factors that drive health disparity may lead to the discovery of novel biomarkers indicative of disease risk and progression as well as avenues for treatment and prevention strategies.

Glycation represents a metabolic susceptibility difference that may provide a biologic link between cancer and the socioeconomic and environmental factors that drive cancer health disparity. It occurs during normal metabolism and is the nonenzymatic glycosylation of sugar moieties to biologic macromolecules such as protein and DNA. Glycation results in the accumulation of reactive metabolites known as advanced glycation end products (AGE; ref. 9). Cellular clearance of AGE metabolites is inefficient and they accumulate in our tissues and organs as we grow older with pathogenic effects. AGEs contribute to diseases such as diabetes, cardiovascular disease, arthritis, and neurodegenerative disorders (9). Failure to remove these highly reactive metabolites can lead to protein damage, aberrant cell signaling, increased inflammatory responses, increased oxidative damage, changes in extracellular matrix composition, and decreased genetic fidelity (10, 11). AGE functions as a ligand activator for RAGE, which is overexpressed in a variety of tumor types, including prostate (11). AGE activation of RAGE is functionally linked to an increased recruitment of immune cells in a broad range of diseases (11, 12). Its stimulation by
AGE induces the transcriptional activation of NF-κB, STAT3, and hypoxia-inducible factor-1α, which results in the expression of immune cytokines such as IL1, IL6, and TNFα (11, 12). Studies support a direct link between RAGE activation and proliferation, survival, migration, and invasion of tumor cells (11, 12). Blockade of RAGE suppresses tumor growth in two independent mouse models (11, 12) and loss of RAGE in inflammatory mouse models confers resistance to induced skin carcinogenesis (11, 12). In castrate-sensitive and castrate-resistant prostate cancer cell lines, AGE was identified as the ligand for RAGE interactions but other ligands (S100B or amphoterin) were not (13). Significantly, apart from their endogenous production during normal metabolism, AGE accumulation is also associated with the socioeconomic and environmental factors that drive cancer health disparity. A sedentary lifestyle and a poor/ unhealthy diet all contribute to health disparity, increase cancer risk, and AGE accumulation pool (14, 15). Consuming foods that are high in sugar/fat, heavily cooked, or highly processed substantially increases the level of AGES within our bodies (14, 15). AGE content in the so-called Western diet has steadily increased over the last 50 years, and it is now a significant contributor to the AGE accumulation pool and to the progression of many chronic diseases (14, 15). In addition, lifestyle choices such as alcohol consumption and smoking also elevate AGE levels, and human (16) and animal studies (17) show that physical activity interventions can help maintain a stable AGE level or may even reduce it.

Because of the common links between the factors that drive cancer health disparity and the increased accumulation of AGE metabolites, we examined AGE levels in serum and prostate tumor specimens and identified a potential race-specific, tumor-dependent pattern of AGE accumulation that may be indicative of disease progression.

Materials and Methods

**Biologic samples**

Upon Institutional Review Board approval, serum and tissue samples were obtained from the Hollings Cancer Center Tissue Biorepository here at the Medical University of South Carolina (Charleston, SC). Serum samples consisted of a cohort of 26 samples: 14 patients (7 African American, 7 European American) with low-grade prostate cancer (Gleason 4–6) and 12 patients (5 African American, 7 European American) with high-grade prostate cancer (Gleason 7–9). A subset of matching tissue sections (N = 8, 2 per dataset) was also obtained for IHC and immunofluorescent tissue staining. Gleason grade was confirmed and IHC examined by a qualified pathologist.

**AGE ELISA**

To examine the levels of AGE in serum, 96-well format Oxi-select ELISAs (Cell Biolabs) were used as directed by the manufacturer. All samples were normalized to total protein concentration in 1× PBS.

**IHC and immunofluorescent tissue staining**

All specimens were formalin fixed and paraffin embedded. Deparaffinized tissue sections were rehydrated, and antigen retrieval performed by heating in a vegetable steamer in 10 mmol/L citrate, pH 6.0, for 30 minutes. Endogenous peroxidase activity was blocked using 0.3% H2O2 in methanol for 30 minutes. Sections were washed and nonspecific binding was blocked using 2.5% horse serum and then incubated overnight at 4°C with target-specific primary antibody at a 1:100 dilution. CML primary antibody (ab27684) was from Abcam. RAGE primary antibody (AB5601) was from Millipore. Sections were fixed in Permount (Invitrogen) and mounted on slides. All sections were examined using an Olympus BX50 microscope and pictures were taken using an Olympus DP 70 camera connected to DP Controller software (Olympus). IHC scores were calculated using the formula: intensity × % positive tumor cells. Intensity staining was scored: 1, weak; 2, intermediate; 3, strong; and 4, very strong. % positive tumor cells were scored: 1, less than 10%; 2, 10% to 30%; 3, 30% to 60%; and 4, 60% to 100% positive cells. Fluorescence was quantified using image J.

**Statistical analysis**

For statistical testing, two-sided Student t tests were done using an Excel spreadsheet. P < 0.05 was considered statistically significant. Pearson correlation analysis was used to examine the correlation between circulating AGE levels and those found in the tumor as well as between tumor AGE levels and RAGE expression in the tumor.

**Results**

**Circulating AGE levels in patients with prostate cancer**

Levels of the AGE metabolite carboxymethyl-lysine (CML) were measured in serum and tissue from patients with prostate cancer by ELISA. CML is extensively studied in animal models of disease, in epidemiologic studies, and with regard to food content (18). It is often used as a marker of total AGES in biologic systems (14). Our analysis (Fig. 1A) shows that circulating CML levels are significantly higher (P = 0.0016) in serum from high-grade prostate cancer patients (Gleason grade 7–10; N = 12) compared with that observed in low-grade prostate cancer patients (Gleason grade 4–6; N = 14). African American men in the United States are 2.5 times more likely to die of prostate cancer than their Caucasian counterparts (2). When the data were further stratified by self-reported race/ethnicity, we found that compared with the European American (EA) patients with prostate cancer (N = 14), circulating AGE metabolite levels were significantly higher in serum from African American patients with (AA) prostate cancer (N = 12; Fig. 1B). This was observed in both the low-grade (P = 0.0003) and high-grade (P = 0.0015) serum (Fig. 1C).
**Tumor AGE levels in patients with prostate cancer**

AGEs accumulate in our tissues as we grow older and promote numerous disease phenotypes (9, 19). To characterize AGE accumulation in prostate tumors, we examined AGE levels in normal (N = 4) and prostate cancer tissue (N = 8) by IHC. Compared with the staining in the noncancer tissue that represents AGE accumulation levels as a consequence of growing older, AGE metabolite staining was significantly higher in the benign (Fig. 1D, black arrows) and malignant (Fig. 1D, white arrows) tumor tissue. We compared AGE levels observed in the circulation to that observed in the tumor. In matched serum (N = 4) and tumor (N = 4) samples, analysis using the Pearson correlation (Fig. 1E) shows a strong positive correlation between circulatory AGE levels and those observed in the tumor (r = 0.8).

To more readily quantify AGE levels in prostate tumors, we examined CML accumulation in the same normal and prostate cancer tissue using immunofluorescent staining. Compared with the levels observed in noncancer prostate tissue, higher CML staining in the tumor tissue was confirmed (Fig. 2A). Stratification of fluorescent intensity by Gleason grade and self-reported race shows that African Americans with either low-grade (AA-LG) or high-grade (AA-HG) prostate cancer had significantly higher (P = 0.003) CML levels than
their European American counterparts (EA-LG; EA-HG; Fig. 2B). Although AGE staining was evident in both the stromal and epithelial compartments, closer analysis of the fluorescent intensity shows that highest AGE accumulation was observed in the tumor epithelial cells with particular high intensity occurring at the cell membrane (Fig. 2C).

**RAGE expression in prostate cancer tissue**

AGEs function as ligand activators for the transmembrane receptor for AGE (RAGE), which is overexpressed in a variety of tumor types (11). In diabetes and cardiovascular disease, RAGE stimulation by AGE induces the transcriptional activation of factors critical for immune response. Silencing of RAGE expression reduces prostate-specific antigen expression and inhibits cell proliferation in prostate cancer cell lines and tumor growth in NUDE mice (20). Studies show that the V-domain of RAGE preferentially interacts with AGEs on prostate cancer cells (13) and that AGE treatment of prostate cancer cells induced both cell growth and invasion (21).

Figure 2. AGE levels are highest in the epithelial tissue of high-grade African American patients with prostate cancer. A, immunofluorescent staining ($\times 10$ magnification) of AGE with an antibody raised against CML in tumor tissue ($N = 8$) compared with noncancer prostate tissue ($N = 4$). B, quantification of the fluorescent intensity observed in five independent microscope fields of European American and African American patients with either low-grade (LG) or high-grade (HG) prostate cancer. C, higher magnification ($\times 40$ magnification) of the immunofluorescent staining in the tumor epithelial cells and the stroma.
To characterize RAGE protein levels in normal (N = 4) and prostate cancer tissue (N = 8), we used IHC staining. Like AGE, compared with noncancer prostate tissue, RAGE was significantly higher in the benign (Fig. 3A, black arrows) and malignant (Fig. 3A, white arrows) tumor tissue. Quantification of fluorescent staining shows that RAGE expression was higher in low-grade versus high-grade prostate cancer confirming published literature and that African Americans with either low-grade or high-grade prostate cancer had significantly higher (P = 0.005) RAGE levels than their European American counterparts (EA-LG; EA-HG; Fig. 3B). Upon analysis by Pearson correlation, AGE tumor levels showed a strong correlation (r = 0.6) to that of RAGE in the same tissue (Fig. 3C).

Discussion

In a limited dataset, our studies provide initial evidence that AGE accumulation may represent a novel metabolic susceptibility marker that may result from a mechanistic link between inflammation, cancer, and factors promoting cancer disparity.

Both AGE accumulation and the Western lifestyle that contributes to the AGE accumulation pool (14, 15) are intrinsically linked with chronic systemic inflammation (11, 12). Experimental, clinical, and epidemiologic studies demonstrate that chronic inflammation can predispose to different types of cancer and contribute to its progression (22). A recent article in this journal reports that chronic inflammation in low-risk benign prostate tissue was positively correlated with increased prostate cancer, especially in high-grade patients (23). The inflammatory environment caused by AGE-mediated activation of the RAGE pathway could facilitate tumor formation and progression by promoting cancer-associated processes such as ECM remodeling, angiogenesis, and metastasis (11, 12). The significance of AGE accumulation as an inflammatory mediator that contributes to the excessive risk and mortality among African American men may arise from the fact that poor diet and a lack of exercise are lifestyle factors particularly prevalent within African American communities who are also known to have and increased burden of inflammation-associated chronic disease. Significantly, differential cytokine expression associated with an increased immune response was found to be a predominant pathway increased in African American patients with prostate cancer (1). A similar race-specific increase in immune response gene copy number and gene expression was also observed in matched radical prostatectomy tissues (24) and in Gleason 6 prostate tumors (4).

Although the Western lifestyle is an exogenous source of AGE metabolite, the oncogenic reprogramming of cellular metabolism may be a significant endogenous source in tumor cells. Tumor cells upregulate glucose metabolism to provide the energy required to sustain accelerated cell growth and progression (i.e., the Warburg effect; ref. 25). Similar to diabetes, AGEs produced by the Warburg effect have the potential to alter cell signaling pathways to increase intrinsic inflammation and promote cancer-associated processes. Significantly, studies indicate that abnormal glucose uptake and the Warburg effect occur earlier in African American women at high risk of breast cancer and there is a growing link between the Warburg effect and the cancer immune response.

A caveat to this study is the small cohort of samples but the results provide compelling preliminary evidence to rationalize large cohort studies to define the full potential of AGE accumulation as a molecular biomarker in cancer and to dissect its functional contribution to cancer onset.
and progression. Given the potential benefits of lifestyle changes and the role of dietary AGE in promoting disease phenotypes, opportunities exist for impacting cancer prevention initiatives arising through health and nutritional education as well as reducing cancer disparity.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: M. Ahmed, M.E. Ford, D.P. Turner
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): D. Foster, L. Spruill, K.R. Walter, R.Y. Turner, V.J. Findlay, D.P. Turner
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): D. Foster, M.E. Ford, V.J. Findlay, D.P. Turner

References
AGE Metabolites: A Biomarker Linked to Cancer Disparity?

Dion Foster, Laura Spruill, Katherine R. Walter, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-14-0564

Cited articles
This article cites 24 articles, 5 of which you can access for free at:
http://cebp.aacrjournals.org/content/23/10/2186.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/23/10/2186.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.